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Abstract
Peroxiredoxin (Prdx) proteins are evolutionarily conserved thiolspecific antioxidant enzymes that reduce various cellular peroxides,
protecting cells from oxidative damage. Prdxs also have been
demonstrated to play an important role in regulating redox-sensitive
cell signaling in a number of cell processes. Prdxs have been
implicated in cancer biology, and are upregulated in many cancers
including breast cancer, as well as several breast cancer cell lines.
To explore the entire Prdx family in breast cancer, we analyzed
the expression of all six Prdx proteins in breast tumor tissue and
adjacent normal breast tissue from 14 patients. We found that most
patients have a marked elevation of Prdx expression in tumor tissue,
with many patients overexpressing multiple Prdxs. Specifically, we
found that 71% of patients overexpress Prdx1, 50% overexpress
Prdx2, 64% overexpress Prdx3, and 57% overexpress Prdx4. In
contrast, Prdx5 and Prdx6 are elevated in a minority of patients.
We found no association, however, between the incidence of Prdx
overexpression and tumor grade in this study. Our findings provide
further evidence for Prdx elevation in breast cancer using matched
patient samples, and support the notion that Prdx upregulation
may provide a survival advantage to breast cancer cells, and other
cancer cells.
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Introduction
The Peroxiredoxins are a family of evolutionarily conserved
thiol-specific antioxidant proteins. These proteins act as peroxidase
enzymes, reducing cellular peroxides (including hydroperoxides and
lipid peroxides) in the presence of specific electron donors [1]. As a
result, peroxiredoxins (Prdxs) protect cells from oxidative damage
associated with normal cellular metabolism [2,3]. Since ROS are now
well characterized signaling molecules, Prdxs are also recognized to
act as modulators of redox signaling, thereby regulating a number of
redox-sensitive processes involved in cell proliferation, differentiation,
and apoptosis [4,5]. In mammals, there are six Prdx proteins, which
can be subcategorized by the number of cysteines in the active site
of the protein. The 2-Cys Prdxs (Prdx1-5) react with peroxides to
form a disulfide bond either as dimers (Prdx1-4) or intramolecularly
(Prdx5) [6]. In contrast, 1 -Cys Prdx (Prdx6) contains only one active
cysteine, cannot form dimers through disulfide bond formation, and
has the unique ability to reduce lipid peroxides [7]. The different
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Prdxs exhibit differences in tissue distribution, cellular localization,
and substrate specificity, therefore demonstrating distinct roles in the
cellular antioxidant defense system [8].
In recent years, the overexpression of Peroxiredoxins in
breast cancer cells has been well documented [9-13]. Although
the precise mechanism of action in these cells has not been fully
elucidated, elevation of other antioxidants in cancer cells suggests
that upregulation of peroxiredoxins provides a survival advantage
to cancer cells in an environment of elevated oxidative stress.
Additionally, research implicating oxidative stress in chemoresistance
supports peroxiredoxins and other antioxidant proteins as potential
candidates for therapy targets [13]. Recent studies have reported
Prdx overexpression correlates with development, recurrence,
and/or progression of cancers, [13-15]. Karihtala and others
reported elevated Prdx 3-5 levels to be associated with more poorly
differentiated tumors, and Prdx 5 with shorter survival in breast
cancer patients [10]. They hypothesized that the increase in Prdx
expression is induced by higher ROS levels in the cancerous state.
However, the correlation with malignancy and disease progression
remains a controversy as many groups have conflicting results
[10,16,17]. Prdx2 and Prdx4 may be of particular interest since they
are secreted proteins and may be useful biomarkers measured in
serum samples [16]. Researchers are continuing to search for reliable
serum biomarkers in breast cancer in the hopes of earlier detection,
and thus better disease prognosis [16,17].
Previous research from our lab has shown overexpression of five
of the six Prdxs at the mRNA and protein levels in the widely studied
MCF-7 human breast cancer cell line, compared to the non-cancerous
MCF-10A cell line [18,19]. We further showed that suppression
of these proteins in MCF-7 cells results in reduced cell viability
[18]. While investigation of the mechanism of Prdx regulation and
function continues in these and other cell lines, it is essential to
pursue Prdx studies in human tumor samples to better understand its
physiological relevance and aberrant in vivo regulation. In addition,
the patient-to-patient variability in Prdx expression, and significant
evidence pointing to Prdx misregulation as an epigenetic cancer
adaption, rather than a causal factor in carcinogenesis, suggests that
proper controls for these experiments will be critical to determine
when and how these Prdxs modify their regulation. As such, we
sought to analyze Prdx protein expression in a number of patient
samples by comparing Prdx levels in breast tumor tissue and adjacent
normal tissue within each patient.
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Table 1: Percent of Patients having elevated tumor Prdx Levels.
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Figure 1: Prdx Expression in Tumor (T) and Adjacent Normal (N) Tissue. (A)
Oncopair INSTAblot IMB-130d, including matched tumor and adjacent nontumor breast tissue for 7 patient donors. Tumor diagnosis for patients are as
follows: P1, mucinous carcinoma; P2, mucinous carcinoma; P3, mucinous
carcinoma; P4, metaplastic; P5, intraductal carcinoma; P6, intraductal
carcinoma; P7, intraductal carcinoma; (B) Oncopair INSTAblot IMB-130a,
including matched tumor and adjacent non -tumor breast tissue for 7 patient
donors. All breast tumors were diagnosed as ductal carcinoma. (*note – the
patient orientation of this blot is reversed from the published order, based on
a difference in loading order for this blot lot).

Materials & Methods
Two OncoPair INSTA-Blots membranes were purchased from
Imgenex/Novus (San Diego, CA). These blots were cat # NBP229911 (IMB-130a) and NBP2-30127 (IMB-130d). Each ready-touse membrane contained denatured protein lysates from ductal
carcinomas and adjacent tissues from seven patient donors. All
patients were females ranging in age from 36-85 years old and
differed in the location and stage of breast cancer. As described
(Imagenex/Novus), all protein lysates were diluted to 1 mg/ml and
equal amounts (14 ug) were loaded onto each lane of a denaturing
gel, electrophoresed and transferred to a PVDF membrane along
with a molecular weight marker. Gel loading corresponds to the
documented information.
Membranes were pre-wet in methanol and rinsed with TBST.
They were blocked in 5% milk in TBST for one hour, incubated
in primary antibody overnight at 4°C, rinsed 5 × 15 min in TBST,
and incubated in the appropriate alkaline phosphatase-conjugated
secondary antibody for one hour at room temperature. After
additional rinses with TBST, the chemiluminescent CDP-Star
Reagent (GE) was used as a substrate, and the blots were imaged with
X-OMAT film (Kodak). The primary antibodies used for the analysis
were from Abcam: anti-Prdx1 (ab59538), anti-Prdx2 (ab15572), antiPrdx3 (ab16751), anti-Prdx4 (ab59542), anti-Prdx5 (ab16944) antiPrdx6 (ab16947) (Abcam, Cambridge, MA).
Band intensities on western blots were quantified with Image J
software. Prdx levels were normalized to control levels and relative
fold differences between tumor and adjacent normal tissue were
calculated for each patient. Correlation coefficients were calculated to
compare tumor grade with incidence of Prdx elevation, for each Prdx.
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We analyzed two patient blots, obtained from Imgenex/Novus. Each
blot contained paired samples of tumor/non-tumor breast tissue from
7 patients, allowing us to analyze a total of 14 patients. Figure 1(A & B)
shows the results of this experiment. As shown in Figure 1, almost all of
the Prdx proteins were detectable in most of the patients, but at varying
levels. Prdx5 was detected at the lowest levels in virtually all patients, and
was undetectable on Blot 130a (Figure 1B).
Our experiment revealed tumor overexpression of multiple Prdx
proteins in nearly all patients, with one patient exhibiting tumor
overexpression of all six Prdx proteins (Figure 1A, P6). In particular,
four patients from blot 130d (Figure 1A) and three patients from blot
130a (Figure 1B) exhibited a very substantial increase in the expression
of several Prdx proteins in the tumor, compared to adjacent tissue.
Interestingly, Prdxs1-4 were overexpressed to the greatest extent in
tumors (Figure 1) and also were overexpressed in the greatest number
of patient tumors. The tumor-specific elevation was over five-fold in
many patients, reaching 15X for Prdx1, 7X for Prdx2, 14X for Prdx3,
and 16X for Prdx4. Interestingly, patient #3 (Figure 1A) exhibited the
highest elevation of Prdx1, Prdx2 and Prdx4. Prdx6 levels reached
7X, while quantification of Prdx5 levels could not be made due to
low signal.
We then quantified the number and percentage of patients who
clearly (and unambiguously) showed elevated expression of each
Prdx. As shown in Table 1, the first four Prdxs were elevated in 71%,
50%, 64%, and 57% of patients, respectively. Finally, we quantified
the number of patients exhibiting overexpression of multiple Prdx
proteins. As shown in table 2, 64% of patients overexpressed two or
more Prdxs in tumor tissue and 50% of patients overexpressed 4 or
more Prdxs in tumor tissue. Of the 14 patients analyzed, we found
only three patients who exhibited little to no Prdx elevation in tumor
tissue (Figure 1A, P2; Figure1B, P3 & P4).
Based on prior conflicting studies regarding the relationship
between Prdx levels and tumor grade, we wanted to examine this in our
samples. The tumor grade for each patient was available from the blot
supplier (Imgenex/Novus). We examined whether the incidence of Prdx
overexpression correlated with tumor grade in these patient samples.
As shown in Figure 1, we found Prdx overexpression in all four tumor
grades (I, II, III and IV), and we saw no particular relationship between
the tumor grade and the incidence of Prdx elevation for any of the Prdx
proteins, as determined by correlation analysis.

Discussion
In the present study, we examined the expression of the six
Peroxiredoxin antioxidant proteins in tumor tissue and adjacent
normal tissue from 14 breast cancer patients. We found that the vast
majority of patients show a marked overexpression of multiple Prdx
proteins in tumor tissue, with Prdx1, 3 and 4 being most frequently
elevated, and by the largest extent. We found no correlation between
incidence of Prdx overexpression and tumor grade.
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Our findings are consistent with other studies that have examined
multiple Prdxs, including studies that specifically found elevated
expression of Prdx1-3 in breast tumors [9], and another showing
elevation in Prdx1, 3, and 4 in a much higher percentage of breast
cancer than either Prdx2 or Prdx6 [10]. However, these other studies
used non-matched normal breast tissue as controls. Since Prdx levels
vary significantly between individuals, our study demonstrating
elevated tumor levels compared to normal breast tissue within the
same individual is more compelling, and more strongly supports a
physiologically important role for Prdx in the cancer process. Our
observations that Prdx1-4 are elevated in most tumors are also
consistent with our previous studies showing overexpression of
Prdxs1 -5 (but not Prdx6) in the MCF7 breast cancer cell line, as
compared to the normal MCF10A line [18,19]. This helps to validate
the use of the MCF7/MCF10A cell lines as an acceptable in vitro model
for further investigation of Prdx regulation and function in breast
cancer. Despite considerable evidence that Prdxs are upregulated
in breast cancer, as well as other cancers, there is virtually nothing
known about the mechanism of this upregulation in these cells.
Our observation that Prdx1-4 are most commonly elevated in
breast tumors is intriguing. A recent review explores new evidence
on the mechanism of action of these 2-Cys peroxiredoxins (Prdx14), revealing their important role in redox-sensitive processes
including proliferation and cancer [20]. Each of these proteins uses
a similar dimeric structure to catalyze the peroxide reaction, and
has a somewhat distinct subcellular localization. Prdx1 has been the
most studied, and is the most abundant Prdx in cells, localizing to the
cytosol. Cha et al. reported overexpression of Prdx1 and Thioredoxin
I in breast carcinoma, using paired samples, and further reported an
association with tumor grade [21]. However, this study compared
fold difference in mRNA levels (not protein) between tumor grade
and type, and examined a much larger set of samples, so it is possible
that we may have observed a correlation with a larger set of samples.
Prdx1 has been found to associate with multiple proteins
including c-Abl [22], and recently, Prdx1 was shown to associate
with MAPK phosphatases (MKP-1 and MKP-5), thereby regulating
redox-signaling in breast cancer in a H202 dose-dependent manner
[23]. Based on its dual-role, it is possible that upregulation of Prdx1 in
breast cancer either serves to protect cancer cells from ROS-induced
damage and/or assists in redox-regulated proliferation and apoptosis.
Prdx2 is another cytoplasmic peroxiredoxin, while Prdx3 is the
primary mitochondrial peroxiredoxin, which is critical for proper
mitochondrial function [24]. Prdx4 is both secreted and found in the
ER, and recently has been implicated in the oxidative protein folding
[25,26]. While upregulation of all four of these peroxiredoxins has
been reported in breast cancer cells, there is little known about their
role in these tumor cells. It is clear that each Prdx has designated
peroxide-detoxifying roles in the cell, and that levels of ROS in all
of these subcellular locations are elevated in cancer cells. A recent
report from our lab demonstrated that suppression of Prdxs 1,2,3
or 5 in MCF7 breast cancer cells significantly reduces resistance to
doxorubicin, while suppression of Prdx3 reduces cell viability even
in the absence of drug treatment [18]. This is the only study, thus far,
that has examined the effect of all six Prdx proteins in breast cancer
cells.
Much additional research is needed to elucidate the precise
role of each Prdx in breast cancer biology, and the mechanism of
its upregulation in tumor cells. But together, our findings further
implicate overexpression of the Prdx family of proteins in breast
cancer as a widespread phenomenon, and support the notion that
Prdx induction may provide cytoprotection for breast cancer cells in
vivo.
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